Representative experience

Novartis on the Series C investment in Pliant Therapeutics Inc., a company focused on discovering and developing novel therapies to slow or halt the progression of multiple fibrotic diseases.

Jazz Pharmaceuticals on the acquisition of Cavion, Inc. a company that creates therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases.

Medigene AG in US$1bn+ deal with bluebird bio to establish a strategic T cell receptor alliance in cancer immunotherapy.

Gilead Sciences on the technology license agreement with Xencor, Inc., a company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma, and allergic diseases.

Novartis on its US$665m acquisition of Selexys Pharmaceuticals and with its landmark portfolio transformation transactions with GSK and Eli Lilly.

A leading Japanese innovator pharmaceutical firm in numerous Hatch-Waxman actions in relation to generic versions of its product.

DepoMed in patent suit and IPRs against Endo Pharmaceuticals relating to Opana® ER; PTAB upheld Depomed's patents on controlled release gastric retentive technology.

Merck Sharp & Dohme in Hatch-Waxman actions against Hospira and Sandoz in relation to Merck’s antibiotic drug, Invanz®.

Serving as national product liability counsel for Bristol-Myers Squibb in a mass tort involving allegations that Abilify causes compulsion gambling.

A global pharmaceutical company on multijurisdictional personal injury litigation and coordinating the client's defense in more than 27 countries.

A biotechnology manufacturer in investigation of multiple whistleblower allegations that the company promoted a surgical implant for off-label use.

Conducted internal investigations at global pharmaceutical companies into allegations of money laundering, international corruption, and fraudulent practices related to asset transfers in multiple countries.